Overview

A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

Status:
Completed

Trial end date:
2020-10-30

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.

Phase:

Phase 2

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Collaborators:

European Network of Individualized Treatment in Endometrial Cancer - ENITEC
European Network of Translational Research in Ovarian Cancer - EUTROC

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel
Serabelisib